Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 6von Hippel-Lindau Disease 3Pheochromocytoma 2Paraganglioma 2Kidney Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Hemangioblastoma 1Endometrial Neoplasms 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

Cyclophosphamide 58Dexamethasone 50Rituximab 39Peripheral Blood Stem Cell Transplantation 29Paclitaxel 29Lenalidomide 28fludarabine phosphate 27Gemcitabine 26Etoposide 26Bortezomib 26Cytarabine 25Busulfan 24pembrolizumab 21Radiotherapy 21Bevacizumab 21Carboplatin 20Mycophenolic Acid 19Melphalan 19Cisplatin 19Filgrastim 18pomalidomide 17fludarabine 17Oxaliplatin 17Antilymphocyte Serum 17Cyclosporine 16Tacrolimus 15Methotrexate 15Whole-Body Irradiation 14Methylprednisolone 13Bendamustine Hydrochloride 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Recurrence × belzutifan × Clear all
NCT03634540 2024-12-20

MK-6482-003

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Active not recruiting
118 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡